Literature DB >> 9825475

Distribution of somatostatin receptors in normal and neoplastic human tissues: recent advances and potential relevance.

J C Reubi1, J C Schaer, R Markwalder, B Waser, U Horisberger, J Laissue.   

Abstract

This short review describes the localization of somatostatin receptors with in vitro receptor autoradiography techniques in several non-classical, normal human somatostatin target tissues as well as in selected human tumors. In addition to brain, gut and neuroendocrine localizations, somatostatin receptors are expressed in most lymphatic tissues, including gut-associated lymphatic tissue, spleen and thymus; in the cortical and medullary area of the kidney; in the stroma of the prostate and in the epithelial cells of the thyroid. Among human tumors, the extremely high density of somatostatin receptors in medulloblastomas should be stressed as well as the favorable prognostic role of the presence of somatostatin receptors in neuroblastomas. Moreover, several types of mesenchymal tumors have somatostatin receptors as well. The receptor subtypes expressed by distinct tumors may vary: Whereas medulloblastomas and neuroblastomas predominantly express sst2, prostate cancers express sst1 rather than sst2. A further emerging somatostatin target is represented by the peritumoral veins, also known to express sst2 receptors. The multiple somatostatin targets in normal and pathological human tissues represents the basis for potential diagnostic and clinical applications of somatostatin analogs.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9825475      PMCID: PMC2589261     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  25 in total

Review 1.  The role of somatostatin and its analogs in the diagnosis and treatment of tumors.

Authors:  S W Lamberts; E P Krenning; J C Reubi
Journal:  Endocr Rev       Date:  1991-11       Impact factor: 19.871

2.  Effect of somatostatin on splanchnic hemodynamics in patients with cirrhosis of the liver and in normal subjects.

Authors:  G E Sonnenberg; U Keller; A Perruchoud; D Burckhardt; K Gyr
Journal:  Gastroenterology       Date:  1981-03       Impact factor: 22.682

3.  Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization.

Authors:  J C Reubi; J C Schaer; B Waser; G Mengod
Journal:  Cancer Res       Date:  1994-07-01       Impact factor: 12.701

Review 4.  Distribution of somatostatin receptors in normal and tumor tissue.

Authors:  J C Reubi; L Kvols; E Krenning; S W Lamberts
Journal:  Metabolism       Date:  1990-09       Impact factor: 8.694

5.  Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane.

Authors:  E A Woltering; R Barrie; T M O'Dorisio; D Arce; T Ure; A Cramer; D Holmes; J Robertson; J Fassler
Journal:  J Surg Res       Date:  1991-03       Impact factor: 2.192

6.  In vitro autoradiographic and in vivo scintigraphic localization of somatostatin receptors in human lymphatic tissue.

Authors:  J C Reubi; B Waser; U Horisberger; E Krenning; S W Lamberts; J O Gebbers; P Gersbach; J A Laissue
Journal:  Blood       Date:  1993-10-01       Impact factor: 22.113

7.  Preferential location of somatostatin receptors in germinal centers of human gut lymphoid tissue.

Authors:  J C Reubi; U Horisberger; B Waser; J O Gebbers; J Laissue
Journal:  Gastroenterology       Date:  1992-10       Impact factor: 22.682

8.  Distribution and biochemical characterization of somatostatin receptors in tumors of the human central nervous system.

Authors:  J C Reubi; W Lang; R Maurer; J W Koper; S W Lamberts
Journal:  Cancer Res       Date:  1987-11-01       Impact factor: 12.701

9.  Human kidney as target for somatostatin: high affinity receptors in tubules and vasa recta.

Authors:  J C Reubi; U Horisberger; U E Studer; B Waser; J A Laissue
Journal:  J Clin Endocrinol Metab       Date:  1993-11       Impact factor: 5.958

10.  Effect of somatostatin on renal function.

Authors:  J P Vora; D R Owens; R Ryder; J Atiea; S Luzio; T M Hayes
Journal:  Br Med J (Clin Res Ed)       Date:  1986-06-28
View more
  22 in total

1.  Gastrin, somatostatin, and experimental disturbance of the gastrointestinal tract in rats.

Authors:  Y L Yao; B Xu; W D Zhang; Y G Song
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

2.  SSR2(a) receptor expression and adrenergic/cholinergic characteristics in differentiated SH-SY5Y cells.

Authors:  Sayed Hossein Hashemi; Jia-Yi Li; Håkan Ahlman; Annica Dahlström
Journal:  Neurochem Res       Date:  2003-04       Impact factor: 3.996

Review 3.  Somatostatin receptor PET ligands - the next generation for clinical practice.

Authors:  Elin Pauwels; Frederik Cleeren; Guy Bormans; Christophe M Deroose
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-10-20

4.  Is there a therapeutic role for octreotide in patients with ectopic Cushing's syndrome?

Authors:  G I Uwaifo; C A Koch; B Hirshberg; C C Chen; P Hartzband; L K Nieman; K Pacak
Journal:  J Endocrinol Invest       Date:  2003-08       Impact factor: 4.256

Review 5.  Octreoscan radioreceptor imaging.

Authors:  Aart J van der Lely; Wouter W de Herder; Eric P Krenning; Dik J Kwekkeboom
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633

6.  Somatostatin Receptors in Lung Cancer: From Function to Molecular Imaging and Therapeutics.

Authors:  J Clay Callison; Ronald C Walker; Pierre P Massion
Journal:  J Lung Cancer       Date:  2011

7.  What can gallium-68 PET add to receptor and molecular imaging?

Authors:  Adil Al-Nahhas; Zarni Win; Teresa Szyszko; Aviral Singh; Sameer Khan; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-12       Impact factor: 9.236

Review 8.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

Review 9.  Arsenic trioxide: insights into its evolution to an anticancer agent.

Authors:  Maneka Hoonjan; Vaibhav Jadhav; Purvi Bhatt
Journal:  J Biol Inorg Chem       Date:  2018-02-02       Impact factor: 3.358

Review 10.  Clinical applications of Gallium-68.

Authors:  Sangeeta Ray Banerjee; Martin G Pomper
Journal:  Appl Radiat Isot       Date:  2013-02-20       Impact factor: 1.513

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.